In an interview with PharmaShots, Dr. Briggs W. Morrison, MD, Chief Executive Officer and Director at Syndax share his views on the license agreement for axatilimab with Incyte to treat […]readmore
Tags : PharmaShots
Generic medicines are the backbone of the healthcare system and are identical to the innovator medicine in strength, effect, dosage form, and route of administration. These are allowed for sale […]readmore
In an interview with PharmaShots, Jonathan Benjamin, MD, Ph.D., Senior Vice President & Clinical Research of Atreca shared his views on the initial data from the dose-escalation portion of its ongoing P-Ib trial for ATRC-101 to treat solid tumor […]readmore
In an interview with PharmaShots, Kevin Cammack, Head of Connected Care, Eli Lilly, and Mark Warren, MD, Director of Endocrine Clinical Trials and Laboratory Services, Physicians East share their views […]readmore
In an interview with PharmaShots, Ron Elwell, President, and Founder of Swoop and IPM.ai shared his views on the Real Chemistry Clinical Trial Recruitment System that is designed to accelerate […]readmore
Shots: PharmaShots has started its journey in July 2018 as a concise, real-time news delivery platform and is proud to announce the completion of three years, with many more to […]readmore
June 22 – 23, 2021 (EDT) | Virtual Conference The American Conference Institute invites you to attend the Virtual 12th Summit on Biosimilars & Innovator Biologics on June 22-23, 2021! Gain government […]readmore
The biopharma industry saw numerous deal terminations in 2020. Clinical and regulatory results, change in control limitations, and strategic reprioritizations were among the most common reasons for deal termination. Sanofi […]readmore
Wearables are electronic devices consisting of sensors that can receive data of user’s personal health and exercise schedules. They work wirelessly or with the help of other devices such as […]readmore
The fourth quarter of 2020 contains multiple initiations of clinical trials, big approvals, and numerous deals. COVID-19 related news remains at the peak in this quarter Multiple companies received regulatory […]readmore